The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
02-Mar-98
$400 million
Target:
Olsy SpA (Olivetti SpA)
Acquiror:
Wang Laboratories Inc.
Advised Wang on its acquisition of Olsy, the systems and solutions division of Olivetti, for a combination of cash and securities.
06-Aug-99
$12.8 billion
Target:
One2One
Acquiror:
Deutsche Telekom AG
(joint venture between Cable and Wireless plc and Media One)
Strategic advice to C&W in connection with the sale of One2One, a UK mobile phone operator, 50% owned by C&W and 50% owned by Media One
30-Jul-01
$117 million
Target:
Kymata Ltd.
Acquiror:
Alcatel Optronics
Advised Kymata Ltd, the Scottish manufacturer of optical components, on its sale to Alcatel Optronics of France.
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
19-Dec-06
$270 million
Target:
Brion Technologies, Inc.
Acquiror:
ASML Holding N.V.
Advised ASML Holding N.V., a leading provider of lithography systems for the semiconductor industry, on its acquisition of Brion Technologies, Inc.
26-Mar-07
$1.0 billion
Target:
Wolters Kluwer Education
Acquiror:
Bridgepoint Capital Limited
Advised Bridgepoint Capital Limited on its acquisition of Wolters Kluwer Education, the pan-European educational publishing division of quoted Dutch-based information services and publishing company Wolters Kluwer NV
02-Jan-08
$NA
Target:
E. Brost & J. Funke GmbH & Co. KG (BFK KG) and its 25% stake in Otto Group
Acquiror:
Otto AG für Beteiligungen (investment vehicle of Otto family)
Advised the shareholders of BFK KG, comprising the families who also own German publisher WAZ Media Group, on the sale of their 25% holding in German retailing and services group Otto to the Otto family, which thereby regained full ownership of the business
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
05-Aug-08
$NA
Target:
BARTEC Group
Acquiror:
Capvis
Advised Capvis, a leading Swiss private equity firm, on its acquisition of the BARTEC Group, a leading European provider of industrial safety technology, from Allianz Capital Partners, the captive private equity arm of Allianz AG, and the Barlian family (founding family)
15-Sep-08
$189 million
Target:
Fermat International
Acquiror:
Moody’s Corporation
Advised Moody’s Corporation on its acquisition of Fermat International, a leading provider of risk and performance management software to the global banking sector
01-Oct-08
$53 million
Target:
Biotage (Biosystems division)
Acquiror:
Qiagen NV
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
04-Dec-09
$NA
Target:
Verivox Holding Limited
Acquiror:
Oakley Capital Private Equity LP
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
27-Jul-11
$850 million
Target:
The Synovate Group
Acquiror:
Ipsos S.A.
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
09-Jul-12
$4.7 billion
Target:
ASML Holding NV (minority stake)
Acquiror:
Customers including Intel Corporation, TSMC and Samsung Electronics
Advised the Supervisory Board of ASML on the establishment of a Customer Co-Investment Program including the issue of 23% equity stake and $1.7 billion of R&D funding
12-Jul-12
$5.0 billion
Target:
Aegis Group plc
Acquiror:
Dentsu Inc.
Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
17-Oct-12
$2.6 billion
Target:
Cymer, Inc.
Acquiror:
ASML Holding NV
Advised ASML Holding NV, a leading provider of lithography systems for the semiconductor industry, on its acquisition of Cymer, Inc., a leading supplier of lithography light sources used by chipmakers to manufacture advanced semiconductor devices
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
03-Mar-14
$3.6 billion
Target:
hibu plc (formerly Yell Group plc)
Advised hibu, a full service provider of digital and print marketing services for SMEs and owner of print directory brands Yellow Pages (UK), Yellowbook (US) and Paginas Amarillas (Spain), on the comprehensive restructuring of its £2.2 billion balance sheet debt
08-Apr-14
$NA
Target:
ARTnews
Acquiror:
Skate Capital Corp.
Advised ARTnews, the world's oldest and most widely circulated art magazine, on its sale to Skate Capital Corp., a private art and media industry investment vehicle